Yahia Gawad, MB. Ch.B., MD., MSc., Founder/CEO and Director
Yahia was a co-founder of Syn X (previously Skye Pharmatech) where he held the position of Vice-President, Medical Affairs and prior to that, he was Director of Clinical Research at Spectral Diagnostics Inc. For the last 18 years, he has been working extensively on cardiac diagnostic test products, which he took from concept and bench development to commercialization, through regulatory approval processes. Dr. Gawad is a Physician/Scientist with primary training in Cardiology, Biochemistry and Immunology.
James A. Essex, CA, MBA, CFO. James has been with CardioGenics since 1999. He founded Hunter & Associates Inc. in 1990, a private financial consulting firm. Previously, he was a co-owner, President and COO of Calais Investigations, Inc., a private company (from 1993 to 1998), a Vice President of Confederation Trust (1989) and a Vice President of Chemical Bank of Canada (now Chase Manhattan Bank of Canada) from 1977 through 1987.
Ms. Linda J. Sterling, F.Inst.L.C.O., Corporate Secretary/Director. Linda has been managing CardioGenics’ legal affairs since 2003. Linda has been in the legal community in the capacity as a Law Clerk with both Stikeman Elliott LLP and Davies Ward Phillips & Vineberg LLP since 1999. She developed expertise with both public and private company legal compliance and has been responsible for CardioGenics' compliance and maintenance of corporate governance since 2001. She is licensed as a Legal Executive (F.Inst.L.C.O.); with the Institute of Law Clerks of Ontario, of which she is a member. She has held the position of CEO and director of Sterling Studios since 1989.
Mr. Neil Tabatznik, Acting Chairman. Neil has been with CardioGenics since 2003. He is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from 0 to 700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by Merck KGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.
Mr. Alexander D.G. Reid, Director. Alexander (Tony) has been an investor and Director in CardioGenics since 1998. Tony has been in the financial community with experience in public and private companies for over 30 years. He has held numerous positions and board memberships in various financial and non-financial corporations. For many years, Mr. Reid was the author of the market business column in the Financial Post. Through his writing, various business models have been analyzed and critiqued. He has been involved with the Company as a shareholder since 1999.
Board of Advisors
Prof. Robert Roberts, MD
Chairman & CEO, Ottawa Heart Institute
Prof. William Kostuk, MD
Professor of Medicine, U. Western Ontario